Logo image
Prof. Dr. med. Andreas Hochhaus working place, University Hospital Jena
Prof. Dr. med. Andreas Hochhaus
Excellent
AiroScore
9.80

Prof. Dr. med. Andreas Hochhaus

internal medicine, hematology, and oncology
internal medicine, hematology, and oncology
User ScoreExperienceTotal ReviewsRatingPrice RangePublicationsOnline Consultations
91%39 years39.8/10$$$$1284No

Overview

Country, City
Germany, Jena
Health facility
University Hospital Jena
Medical unit
Department of hematology, oncology, and palliative medicine
3.7 on Google
The data collected based on 3 patient reviews on Google

About the doctor

Prof. Dr. med. Andreas Hochhaus is a highly experienced doctor specializing in internal medicine, hematology, and oncology. With over 38 years of experience, he has made significant contributions to leukemia research and treatment. He has an impressive academic background, including obtaining a license for medical practice, defending his dissertation, and receiving additional qualifications in hematology and oncology. In 1997, he got his habilitation and teaching license in internal medicine from the University of Heidelberg. Prof. Hochhaus has held numerous prestigious positions throughout his career. He has worked as a senior physician at the III Mannheim Medical Clinic at the University of Heidelberg and as a leukemia research and internal medicine professor at the Friedrich Schiller University Jena. He is the director of the Department of Hematology, Oncology, and Palliative Medicine at the University Hospital Jena. A notable aspect of Prof. Hochhaus' career is his involvement in scientific publications. He has authored a staggering 1269 publications, focusing on various aspects of leukemia and its treatment. This showcases his dedication to advancing knowledge in his field and his commitment to improving patient care. Prof. Hochhaus' expertise and extensive experience make him a highly respected and sought-after doctor in Germany.

Skills & Expertise

leukemia
myeloid leukemia
imatinib
nilotinib
dasatinib
cancer
myelogenous leukemia
ponatinib
mutation
stem cell transplantation
interferon
bosutinib
rectal cancer
capecitabine
lymphoblastic leukemia
bcrabl mutations
blast crisis
allogeneic stem cell
neoplasms
hematology
asciminib
malignancies
tumor
oncology
hematopoietic stem cell
chemotherapy
imatinibresistant chronic myeloid
bone marrow
colorectal cancer
systemic mastocytosis
chemoradiotherapy
myeloproliferative neoplasms
multiple myeloma
gastric cancer
internal medicine
hemophagocytic lymphohistiocytosis
eosinophilic leukemia
hypereosinophilic syndrome
myeloid blast
myeloid blast crisis
metastatic colorectal cancer
polycythemia
promyelocytic leukemia
hematological malignancies
epithelial tumor
thrombocythemia
cytogenetic aberrations
lymphoid blast
gastrointestinal cancer
colon

Resume

CV (Curriculum Vitae)

Education
  • 1979-1985 Studied human medicine at the University of Leipzig and the Medical Academy in Erfurt
  • Obtaining a license for medical practice
  • Defense of the dissertation
  • 1989 Obtaining specialization in internal medicine
  • 1994 Received additional qualifications in the field of hematology and oncology
  • 1997 Habilitation and a teaching license in internal medicine at the Mannheim medical faculty
  • from the University of Heidelberg
Experience
  • 1985-1989 Assistant Doctor at the Department of internal medicine of the Erfurt Medical Academy
  • 1990-1997 III Mannheim medical clinic at the University of Heidelberg
  • 1997-2009 Senior Physician of the III Mannheim medical clinic at the University of Heidelberg
  • 2007 W3 Professorship for leukemia research at the Mannheim medical faculty of the University of Heidelberg
  • 2009 W3 Professorship for internal medicine, hematology, and internal oncology at the Friedrich Schiller University Jena
  • 2009 Director of the Department of hematology, oncology, and palliative medicine at the University Hospital Jena
  • 2010-2020 Vice Dean for research at the faculty of medicine of the Friedrich Schiller University Jena
Awards & Memberships
  • 1990 Member of the German Society for Hematology and Oncology
  • 1999 Co-Applicant and Member of the board at the Competence Network "Acute and chronic leukemia"
  • 2001 Member of the German Cancer Society
  • 2002 Patent holder: "Mutated abl kinase domains"
  • 2002 Patent holder: "Organic compounds"
  • 2002 Member of the working group for internal oncology
  • 2003 Co-Applicant and Member of the steering board at the European LeukemiaNet
  • 2003-2012 Advisory Board Member of the German Society for Hematology and Oncology
  • 2004 Patent holder: "Eleven BCR-ABL tyrosine kinase mutations during imatinib therapy"
  • 2006 Patent holder: "Organic compounds"
  • 2007-2013 Board Member of the working group for internal oncology
  • 2008 Patent holder: "Methods Of Identifying And Treating Individuals Exhibiting Mutant Bcr/Abl Kinase Polypeptides"
  • 2008 Patent holder: "Organic compounds"
  • 2008 Patent holder: "Mutated Abl Kinase Domains"
  • 2009 Member of the Thuringian Cancer Society
  • 2009 Patent holder: “Mutated ABL kinase domains”
  • 2010 Spokesman for the University Tumor Center at the Jena University Hospital
  • 2010 Patent holder: "Organic compounds"
  • 2010-2022 Member of the council of the faculty of medicine at the Jena University Hospital
  • 2011 Chairman of the Thuringian Cancer Society
  • 2012 Board Member of the German Cancer Society
  • 2014 Editor-in-Chief of the LEUKEMIA
  • 2014 Member of the Academy of Non-Profit Sciences in Erfurt
  • 2016 Congress President of the German Society for Hematology and Oncology
  • 2018 Member of the Saxon Academy of Sciences in Leipzig
  • 2019-2023 Member of the Advisory Board of German Cancer Aid
  • 2020 Congress President of the German Cancer Society

Languages

English flag
English
German flag
German

Publications

Nuclear war and physicians' social responsibility.

12 September, 2023

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European leukemia net risk classification.

7 September, 2023

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

September, 2023

Location

Am Klinikum, 1, 07747 Jena, Germany

FAQ

Where does the doctor practice?

What is the specialization of Prof. Dr. med. Andreas Hochhaus?

The primary specialization of the doctor is internal medicine, hematology, and oncology.

What is the experience of the specialist?

Prof. Dr. med. Andreas Hochhaus has been practicing for more than 39 years.

What do patients say about Prof. Dr. med. Andreas Hochhaus?

The doctor has 0 review on AiroMedical and and 3 feedbacks at other places. The UserScore of the specialist is 91%.

What is the rating of the doctor?

What topics does Prof. Dr. med. Andreas Hochhaus expert at?

The doctor has excellent knowledge in leukemia, myeloid leukemia, imatinib, nilotinib, dasatinib.

Is the specialist involved in the research?

Does the specialist offer online consultations?

No, Prof. Dr. med. Andreas Hochhaus doesn’t perform virtual appointments.

Prof. Dr. med. Andreas Hochhaus
Prof. Dr. med. Andreas Hochhaus

Get individual treatment plan and cost estimate. Non-binding 100% free assessment.

© Prof. Dr. med. Andreas Hochhaus

Similar Doctors

Excellent
AiroScore
9.80
University Hospital Jena
internal medicine, pulmonology, and allergology
Excellent
AiroScore
9.80
University Hospital Jena
internal medicine and geriatrics
Excellent
AiroScore
9.80
University Hospital Jena
internal medicine, gastroenterology, diabetology and infectiology
Excellent
AiroScore
9.80
University Hospital Jena
internal medicine, nephrology, diabetology and rheumatology
Excellent
AiroScore
9.80
Excellent
AiroScore
10.00
University Hospital Charite Berlin
pediatrics, hematology, oncology, pediatric intensive care
Excellent
AiroScore
10.00
University Hospital Charite Berlin
cardiology, internal medicine, and intensive care
Excellent
AiroScore
10.00